Neutrophil apoptosis, proinflammatory mediators and cell counts in bronchiectasis

A P Watt, V Brown, J Courtney, M Kelly, L Garske, J S Elborn, M Ennis

Background: Lower airway secretions from patients with bronchiectasis show inflammatory cell infiltration and increased proinflammatory mediators. The aim of this study was to investigate the effects of antibiotic treatment for exacerbations on neutrophil apoptosis and necrosis.

Methods: Sputum was induced from 15 subjects with idiopathic bronchiectasis at the beginning of an acute exacerbation and after intravenous antibiotic treatment. Neutrophil apoptosis and necrosis were assessed using flow cytometry and morphology and the supernatant was analysed for concentrations of inflammatory mediators.

Results: Neutrophil numbers ($\times 10^6$ cells/g sputum) in sputum were significantly greater on day 0 than on day 14 (median difference (95% confidence interval (CI)) 5.14 (1.27 to 8.46), $p = 0.02$). Controls had a significantly higher percentage of sputum macrophages than patients with bronchiectasis (day 0, 1.35 (95% CI 0.48 to 2.89), $p = 0.004$; day 14, 1.09 (95% CI 0.26 to 2.86), $p = 0.02$). The concentrations of tumour necrosis factor $\alpha$ (pg/ml), interleukin 8 (ng/ml), and neutrophil elastase (ng/ml) in sputum supernatant were significantly reduced on day 14 compared with day 0 (median difference $-94$ (95% CI $-158$ to $-27$), $p = 0.005$; $-106$ (95% CI $-189$ to $-50$), $p = 0.0006$; and $-73451$ (95% CI $-135495$ to $-12303$), $p = 0.02$ respectively). Patients with bronchiectasis had a significantly lower percentage of cells which were neither apoptotic nor necrotic than healthy controls (both days, $-38.8$ (95% CI $-49.6$ to $-8.5$), $p = 0.002$; $-45.0$ (95% CI $-58.0$ to $-34.1$), $p = 0.0003$, respectively), and on day 14 they had a significantly higher percentage of secondary necrotic cells than healthy controls (40 (95% CI 11.6 to 57.5), $p = 0.004$).

Conclusions: This study shows that antibiotic treatment affects concentrations of proinflammatory mediators and cell death and clearance may be altered in bronchiectasis.

METHODS

Patients

Fifteen patients with bronchiectasis and 10 healthy control subjects participated in the study. Patients were characterised as having bronchiectasis based on a history consistent with the disease and a computed tomographic (CT) scan of the
chest or bronchogram showing pathological changes consistent with bronchiectasis. A bronchiectasis exacerbation was defined as an increase in symptoms (increased purulence and/or volume of sputum, increased shortness of breath) consistent with an infective exacerbation requiring admission to hospital for an intravenous course of antibiotics. Patients with cystic fibrosis, ciliary disorders, immunodeficiency as a cause of bronchiectasis, any medical condition considered to preclude induction of sputum, or who had received an intravenous course of antibiotics in the previous month were excluded from the study. A blood sample was also taken for measurement of C reactive protein (CRP) concentrations, white cell count, and neutrophil count.

Informed written consent was obtained from all patients. The study was approved by the ethics committee of The Queen's University of Belfast and carried out in accordance with the Declaration of Helsinki (1989).

Sputum induction

Sputum induction was performed using the Sonix 2000 nebuliser (Clement Clarke International Ltd, Harlow, UK) adapting methods described elsewhere.12 13 Sputum was induced from patients on admission to hospital and following a 14 day course of intravenous antibiotics. In brief, 5% saline was nebulised for 20 minutes. Spirometric parameters were assessed in all participants as well as reversibility to salbutamol. Oxygen saturation and pulse rate were recorded throughout (Sat-Trak pulse oximeter; SensorMedics, Bilthoven, The Netherlands). Nebulisation was stopped if forced expiratory volume in 1 second (FEV1) fell by >20% at any stage. If this occurred, salbutamol (200 μg) was administered as necessary. Sputum was collected in a sterile plastic pot placed on ice.

Sputum processing

Sputum samples were processed within 2 hours. The total weight of the sample was recorded. Sputum plugs were selected and processed, adapting methods described by Pavord et al.12 13 The supernatant was removed from the cell pellet and stored at −70°C for future analysis. Cell viability was determined by the trypan blue exclusion method. Cytospin slides were made and stained with Diff Quik. Cytokine concentrations in the supernatant were measured using a quantitative sandwich immunoassay (Pelikine Compact ELISA kits). Neutrophil elastase (NE) was measured using a quantitative continuous (kinetic) assay.14 Sputum was cultured for identification of major pathogens using routine microbiological methods as outlined by the United Kingdom Cystic Fibrosis Trust.15 CRP levels were measured by nephelometry.

Flow cytometry

Cell suspensions (1 × 10^6 cells/ml) were washed twice with phosphate buffered saline/1% bovine serum albumin (PBS/1% BSA) and resuspended in the binding buffer supplied with the annexin V-fluorescein isothiocyanate (FITC; Pharmingen). Cell suspensions were then labelled with annexin V-FITC (AV) and propidium iodide (PI). The cells were mixed gently and incubated at room temperature for 15 minutes in the dark, then washed once in PBS/1% BSA. Cells were finally resuspended in binding buffer (500 μl) and analysed by flow cytometry within the hour. A Coulter Epics Elite flow cytometer with an argon ion laser was used for analysis of cells. Sputum cells were gated on a granulocyte population using a forward scatter and side scatter plot. Negative controls from which AV and PI were omitted were used as positive controls and are readily accessible for detection of apoptosis. To eliminate cellular debris from the analysis the discrimination level was set at 100. Analysis of samples was performed using the Immuno 4 software programme which involved subtraction of negative controls from positive samples.

Morphology

Eleven cytospin slides from patients at day 0 and nine cytospin slides from patients at day 14 were evaluated by light microscopy for the presence of apoptotic cells. A number of slides (four on day 0 and six on day 14) did not have enough cells to count or were uncountable due to large amounts of cellular debris. In order to evaluate the proportion of apoptotic cells in neutrophils recovered from sputum, at least 500 neutrophils were graded for apoptosis on each cytospin slide. Cells showing typical features of apoptosis such as nuclear chromatin condensation, nuclear coalescence, and cell shrinkage were considered as apoptotic.16

Statistical analysis

Results are reported as median difference (95% confidence intervals). Data that were not normally distributed were analysed using the non-parametric Mann-Whitney two sample (non-matched) test and Wilcoxon matched pair test. A p value of <0.05 was considered statistically significant. When the measured mediator concentration was below the detection limit of the assay, a value equal to the detection limit for that assay was substituted for the statistical analysis. Statistical analysis was performed using Graphpad PRISM Version 3.0. Median differences and confidence intervals were calculated using MiniTab.

RESULTS

Fifteen patients with bronchiectasis and 10 healthy controls completed the study; their demographic data are shown in table 1. The patients were recruited consecutively, so they comprise a heterogeneous group treated with various antibiotics (table 2). Nine of the patients were receiving inhaled steroids and two of these patients were also taking oral prednisolone. As the microorganism cultured from the sputum was unknown upon admission, antibiotics were chosen on the basis of the last available sputum culture and antibiogram.

Infection

All patients were treated with antibiotics for 14 days (table 2); 10 of the 15 subjects had bacteria cultured from their sputum on day 0. In seven of these 10 cases there was either no growth or insignificant commensals on day 14; two remained infected with P aeruginosa and there was insufficient sample in one case. Of the five subjects who were initially culture negative, two were culture positive on day 14 (patients 8 and 10).

Lung function

FEV1 (litres or percentage predicted) did not change significantly over the period studied (table 1). There was no significant difference in FEV1 between those with or without detectable infection, nor did it change at any of the time points studied. FEV1 (l) correlated negatively with total cells/g sputum (r = −0.58, p = 0.024) and IL-8 levels in sputum sol (r = −0.73, p = 0.002).

CRP, blood neutrophils, and white cell counts

At day 14 CRP levels were significantly lower than on day 0 (p = 0.007, table 1). In contrast, blood neutrophils (×10^9 cells/l) and total white cell counts were not significantly different (table 1).
Sputum cell counts
A number of slides (four on day 0 and five on day 14) did not have enough cells to count or were uncountable because of large amounts of cellular debris. This may have been due partly to the high mucus content of the samples. The total number of cells isolated per g sputum did not differ significantly between visits. The number of neutrophils in the sputum of patients with bronchiectasis on day 0 was significantly higher than on day 14 (median difference 5.14 (95% CI 1.27 to 8.46), p = 0.02, Wilcoxon matched pairs test) and than control sputum (median difference 2.91 (95% CI 1.27 to 8.46), p = 0.02, Wilcoxon matched pairs test) and control patients at both day 0 and day 14 (median difference −38.8 (95% CI −49.6 to −8.5), p = 0.002 and −45.0 (95% CI −58.0 to −34.1), p = 0.0003, respectively). On day 14 patients with bronchiectasis had a significantly higher percentage of secondary necrotic cells (AV+PI+) than controls (median difference 40 (95% CI 11.6 to 73.5), p = 0.004). Figures S2A and B (available online at www.thoraxjnl.com/supplemental) show typical dot plots obtained from the analysis of induced sputum from a bronchiectasis patient.

Supernatant mediators
The concentrations of tumour necrosis factor α (TNFα (pg/ml)), IL-8 (ng/ml), and NE (ng/ml) were significantly reduced on day 14 compared with day 0 in sputum sol (median difference −94 (95% CI −158 to −27), p = 0.046; −106 (95% CI −189 to −50), p = 0.0006; and −73 451 (95% CI −135 495 to −12 303), p = 0.02 respectively; fig 4).

IL-10 concentrations were also measured. However, of the 30 samples tested (two per patient each taken on days 0 and 14), 18 had undetectable amounts of IL-10 (sensitivity 5 pg/ml). In the remaining 12 samples a mean (SE) concentration of 66 (6) pg/ml was detected.

DISCUSSION
The main aim of this study was to compare levels of neutrophil apoptosis and necrosis during an exacerbation of bronchiectasis before treatment and following a 14 day intravenous course of antibiotics, comparing two time points in the dynamic process which is cell death and clearance. We also determined the levels of the inflammatory mediators IL-8, NE, TNFα and cell numbers in sputum, our hypothesis being that levels of apoptosis and necrosis will change

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Mean (SE) demographic data of study patients</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bronchiectasis patients</strong></td>
<td><strong>Day 0</strong></td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td>55.3 (2.9)</td>
</tr>
<tr>
<td><strong>Sex (F/M)</strong></td>
<td>10/5</td>
</tr>
<tr>
<td><strong>FEV₁ (% predicted)</strong></td>
<td>58.4 (6.7)</td>
</tr>
<tr>
<td><strong>C reactive protein (mg/ml)</strong></td>
<td>54.9 (23.0)</td>
</tr>
<tr>
<td><strong>Blood neutrophils (×10⁶ cells/l)</strong></td>
<td>7.2 (1.2)</td>
</tr>
<tr>
<td><strong>White cell count (×10⁶ cells/l)</strong></td>
<td>10.6 (1.0)</td>
</tr>
<tr>
<td><strong>Total cells (×10⁶/g sputum)</strong></td>
<td>6.4 (1.1)</td>
</tr>
<tr>
<td><strong>FEV₁</strong> = forced expiratory volume in 1 second.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Antibiotic treatment administered to each patient for 14 days beginning at day 0 and microorganisms cultured in sputum samples at day 0 and day 14</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patient no</strong></td>
<td><strong>Treatment</strong></td>
</tr>
<tr>
<td>1</td>
<td>Cefotaxime/gentamicin</td>
</tr>
<tr>
<td>2</td>
<td>Augmentin</td>
</tr>
<tr>
<td>3</td>
<td>Tazocin/lobaramycin</td>
</tr>
<tr>
<td>4</td>
<td>Tazocin/gentamicin</td>
</tr>
<tr>
<td>5</td>
<td>Tazocin/lobaramycin</td>
</tr>
<tr>
<td>6</td>
<td>Cefazidime</td>
</tr>
<tr>
<td>7</td>
<td>Cefazidime/fluocoxacin</td>
</tr>
<tr>
<td>8</td>
<td>Cefazidime/aztreonam</td>
</tr>
<tr>
<td>9</td>
<td>Cefazidime</td>
</tr>
<tr>
<td>10</td>
<td>Cefazidime</td>
</tr>
<tr>
<td>11</td>
<td>Meropenem/gentamicin/ nebulised colistin</td>
</tr>
<tr>
<td>12</td>
<td>Cefazidime</td>
</tr>
<tr>
<td>13</td>
<td>Cefazidime</td>
</tr>
<tr>
<td>14</td>
<td>Cefazidime</td>
</tr>
<tr>
<td>15</td>
<td>Cefazidime/gentamicin</td>
</tr>
</tbody>
</table>
throughout the course of a bronchiectasis exacerbation thereby influencing the inflammatory milieu of the lung.

No significant differences were found between the levels of apoptotic or necrotic granulocytes at the two time points studied, although levels of IL-8, TNFα, NE, and CRP were reduced while a reduction in sputum neutrophils was also recorded. Few studies have investigated neutrophil cell death in sputum from bronchiectasis patients. Vandivier et al. studied apoptotic cells in patients with bronchiectasis during a clinical exacerbation and found that patients with non-CF bronchiectasis had higher levels of apoptotic neutrophils than patients with chronic bronchitis. The levels of apoptotic cells observed in this study are lower than those found by Vandivier et al. at both time points studied. Ten of the patients on day 0 and nine on day 14 had apoptotic levels of less than 10%. Low levels of apoptosis (1.6%) have been reported in the bronchoalveolar lavage (BAL) fluid of patients with bacterial pneumonia. While this may be beneficial in the removal of bacterial infection, this is not the case in chronic inflammatory lung disease. Matute-Bello et al. found a low proportion of apoptotic neutrophils in the BAL fluid of patients with acute respiratory distress syndrome (ARDS) and, similar to our findings, this low proportion remained constant throughout the course of ARDS. They also found no significant difference in the percentage of apoptotic neutrophils between patients with ARDS who lived and those who died.

One possible explanation for the low levels of apoptosis observed in patients with bronchiectasis is inhibition of apoptosis by inflammatory mediators such as IL-8 and TNFα. High levels of TNFα and IL-8 have consistently been found in the expectorated bronchial secretions of patients with bronchiectasis. This suggests a key role for these cytokines in neutrophil influx into lung tissue and sustaining the intense local inflammatory response in the affected bronchial tree. In this study we found that levels of IL-8 and TNFα decreased after antibiotic treatment as previously observed in patients with cystic fibrosis.
significant reduction in neutrophil numbers in sputum was also observed following antibiotic treatment. This decreased neutrophil recruitment to the lung compartment is consistent with the decreased levels of IL-8 and TNFα observed between day 0 and day 14. However, in the vicious cycle of infection and inflammation which occurs in bronchiectasis, it is not possible to assess which event occurs first—decreased cytokine levels leading to decreased neutrophil recruitment or decreased recruitment of activated neutrophils leading to lower levels of inflammatory cytokines. Whichever way events occur, the pathway in the “cycle” concerning the dynamics of cell death appears unaffected. The reduction in the anti-apoptotic cytokines IL-8 and TNFα may have been expected to be accompanied by an increase in apoptotic neutrophils, but it appears that the reduction in inflammatory cytokines is not sufficient to increase the number of apoptotic cells. Other inflammatory mediators have been found to inhibit apoptosis such as IL-6, granulocyte colony stimulating factor, granulocyte-macrophage colony stimulating factor, and leukotriene B4. Phagocytosis of dying cells before they undergo secondary necrosis prevents release of toxic proinflammatory mediators inhibits release of proinflammatory cytokines and stimulates production of anti-inflammatory mediators such as IL-10. It has been hypothesised that decreased levels of anti-inflammatory cytokines in the airways contribute to the development of chronic airway inflammation. It is therefore not surprising that IL-10 was undetectable in the majority of bronchiectasis samples. Macrophage numbers did not change between patient visits, but healthy controls had a significantly higher percentage of macrophages present in their sputum and a significantly lower percentage of secondary necrotic cells at both time points studied, which suggests that clearance of apoptotic cells may be hindered in patients with bronchiectasis due to lower macrophage numbers.

Alternatively, phagocytic recognition mechanisms may be impaired. It has been suggested that cleavage of the phosphatidylinerse receptor by NE specifically disrupts the phagocytosis of apoptotic cells. Our data show a decrease in NE following antibiotic treatment, although we found no correlation with the percentage of secondary necrotic cells present in sputum. This decrease in NE is probably related to the decreased levels of IL-8 and TNFα observed at day 14 resulting in decreased priming and activation of neutrophils.

The total number of cells isolated per gram sputum decreased between days 0 and 14, although not significantly; however, neutrophil numbers were significantly decreased in the sputum at day 14 compared with day 0. This may have been expected to alter the percentage of apoptotic/necrotic neutrophils observed on day 14 in comparison with day 0, but this was not the case. A probable explanation is that, although significantly fewer neutrophils were recruited to the lung compartment on day 14, there was no equivalent significant increase in macrophage numbers. Macrophage clearance of neutrophils remains unaltered, so on day 14 apoptotic cells are still proceeding along the secondary necrotic pathway. A parallel mechanism in which phagocytic clearance by macrophages was accelerated in addition to fewer neutrophils entering the lung would be required to observe differences in the percentage of apoptotic/necrotic cells.

Antibiotic and inhaled steroid treatment may affect levels of apoptotic neutrophils in the lung. This study cannot comment on this aspect because of the heterogeneity of the treatments used. Although there were no significant changes in cell death, an increase in lung function might have been expected to accompany the observed reduction in inflammatory mediators. However, FEV1 (either in litres or percentage predicted) did not alter significantly over the period studied, nor was it altered by the presence of detectable infection. Lack of improvement in lung function in patients with bronchiectasis has previously been reported and may reflect underlying irreversible airway damage in this group.

The isolation of bacteria from sputum culture did not seem to have an effect on granulocyte apoptosis. Thirteen of the 15 patients had positive sputum culture for infection on at least one of the visits, indicating how susceptible this patient group is to infection. However, the microorganism data may not be truly indicative of the infective status of the lung. Eradication of P aeruginosa is unlikely as the bacteria have evolved mechanisms to evade host defences and withstand antimicrobial treatment. Molecular methods such as polymerase chain reaction (PCR) may be able to detect a number of pathogenic bacteria present in a viable state in the lungs but are not identified by routine culture. Severe pulmonary inflammation has been documented in cystic fibrosis without any evidence of infection. Tsang and co-workers showed that there was no correlation between sputum bacteria with either inflammatory or enzymatic factors, leading to the hypothesis that inflammation in bronchiectasis could be partly independent of the infective process.

This study has shown that treatment of an exacerbation of bronchiectasis with a 14 day course of intravenous antibiotics lowers sputum cytokine levels and neutrophil numbers.
Concentrations of these inflammatory indices might provide a useful tool in monitoring disease progression, as there is currently no gold standard for measuring inflammation in bronchiectasis. No significant differences were found in the percentages of apoptotic and necrotic cells before and after antibiotic treatment. Patients with bronchiectasis had higher percentages of cells which were secondarily necrotic and lower percentages of cells which were viable than healthy controls. This, coupled with lower macrophage counts than controls and high levels of inflammatory mediators, suggests that cell death and clearance may be altered in patients with bronchiectasis.

ACKNOWLEDGEMENTS

The authors acknowledge Dr C Goldsmith, Department of Bacteriology, Belfast City Hospital for providing the results of sputum culture, Dr Lorraine Martin and Mrs Kelly Moffitt, School of Pharmacy, The Queen’s University of Belfast for measurement of neutrophil elastase, and Dr Chris Patterson, Department of Epidemiology and Public Health, The Queen’s University of Belfast for assistance with statistical analysis.

Figures S1 and S2 are available online at www.thoraxjnl.com/supplemental.

Authors’ affiliations

A P Watt, V Brown, J Courtney, M Kelly, L Garske, J S Elborn, M Ennis, Respiratory Research Group, Centre for Infection, Inflammation and Repair, The Queen’s University of Belfast, Belfast, UK.

Funding: Department of Employment and Learning, Northern Ireland Chest, Heart and Stroke Association, Research and Development Office.

REFERENCES


Neutrophil apoptosis, proinflammatory mediators and cell counts in bronchiectasis

A P Watt, V Brown, J Courtney, M Kelly, L Garske, J S Elborn and M Ennis

*Thorax* 2004 59: 231-236
doi: 10.1136/thx.2003.008037

Updated information and services can be found at:
http://thorax.bmj.com/content/59/3/231

*These include:*

**Supplementary Material**
Supplementary material can be found at:
http://thorax.bmj.com/content/suppl/2004/02/27/59.3.231.DC1

**References**
This article cites 36 articles, 9 of which you can access for free at:
http://thorax.bmj.com/content/59/3/231#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections
  - Inflammation (1020)
  - Drugs: infectious diseases (968)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/